Sanwa and Kowa strike DPP-4 alliance
This article was originally published in Scrip
Executive Summary
Sanwa Kagaku Kenkyusho has licensed its pipeline DPP-4 inhibiting antidiabetic SK-0403 to Kowa for joint development and commercialisation in Japan, in an alliance which should enable it to compete more effectively in this new product class.